1
|
Poorthuis MH, Brand EC, Hazenberg CE, Schutgens RE, Westerink J, Moll FL, de Borst GJ. Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. J Vasc Surg 2017; 65:1519-1527.e26. [DOI: 10.1016/j.jvs.2016.11.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 11/10/2016] [Indexed: 10/20/2022]
|
2
|
Johnson TR, Tobias JD. Initial Experience with Tissue Plasminogen Activator in Two Pediatric Oncology Patients. J Intensive Care Med 2016. [DOI: 10.1177/088506660001500105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
With the more frequent use of central venous catheters in children for therapeutic interventions such as the administration of chemotherapy and total parenteral nutrition, there has been an increased recognition of thrombotic complications including thrombotic occlusion, deep venous thrombosis, and superior vena cava syndrome. In the symptomatic child, treatment may be warranted to prevent the sequelae of venous thrombosis including embolic phenomena, secondary bacterial infection, as well as post-thrombotic changes in an extremity. One option for treatment is the use of a thrombolytic agent such as tissue plasminogen activator (TPA). The authors present two children who developed thrombotic complications of central venous devices. TPA successfully resolved the clot and reversed the clinical signs and symptoms of venous obstruction. The literature concerning the use of TPA in pediatric patients, its application in such situations, adverse affects, and dosing regimens are presented.
Collapse
Affiliation(s)
| | - Joseph D. Tobias
- From the Department of Child Health, University of Missouri, Columbia, MO
- From the Department Anesthesiology, University of Missouri, Columbia, MO
| |
Collapse
|
3
|
Patel NH, Krishnamurthy VN, Kim S, Saad WE, Ganguli S, Gregory Walker T, Nikolic B. Quality Improvement Guidelines for Percutaneous Management of Acute Lower-extremity Ischemia. J Vasc Interv Radiol 2013; 24:3-15. [DOI: 10.1016/j.jvir.2012.09.026] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Revised: 09/15/2012] [Accepted: 09/17/2012] [Indexed: 11/26/2022] Open
|
4
|
Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia. Cardiovasc Intervent Radiol 2011; 34:1123-36. [PMID: 21882081 DOI: 10.1007/s00270-011-0258-z] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2010] [Accepted: 07/27/2011] [Indexed: 02/08/2023]
Abstract
Percutaneous catheter-directed intra-arterial thrombolysis is a safe and effective method of treating acute and subacute lower limb ischemia, as long as accurate patient selection and procedural monitoring are ensured. Although larger, controlled trials are needed to establish the role of PTDs in ALI, mechanical thrombectomy could currently be applied combined with lytic infusion in selected cases where rapid recanalization is required or as a stand-alone therapy when the administration of thrombolytic agents is contraindicated.
Collapse
Affiliation(s)
- Dimitris Karnabatidis
- Department of Radiology, Patras University Hospital, School of Medicine, Rion, Greece.
| | | | | | | |
Collapse
|
5
|
Abraham-Igwe C, Siddiqui M, Geddes L, Halls J, Irvine A, Browning N. A retrospective study examining thrombolysis for occluded femoro-popliteal grafts – Is it worthwhile? Int J Surg 2011; 9:632-5. [DOI: 10.1016/j.ijsu.2011.07.431] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Revised: 07/09/2011] [Accepted: 07/26/2011] [Indexed: 11/25/2022]
|
6
|
Quality Improvement Guidelines for Percutaneous Management of Acute Limb Ischemia. J Vasc Interv Radiol 2009; 20:S208-18. [DOI: 10.1016/j.jvir.2009.04.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
7
|
Rajan DK, Patel NH, Valji K, Cardella JF, Bakal C, Brown D, Brountzos E, Clark TWI, Grassi C, Meranze S, Miller D, Neithamer C, Rholl K, Roberts A, Schwartzberg M, Swan T, Thorpe P, Towbin R, Sacks D. Quality Improvement Guidelines for Percutaneous Management of Acute Limb Ischemia. J Vasc Interv Radiol 2005; 16:585-95. [PMID: 15872313 DOI: 10.1097/01.rvi.0000156191.83408.b4] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- Dheeraj K Rajan
- Department of Radiology, University of Health Network, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Shortell CK, Queiroz R, Johansson M, Waldman D, Illig KA, Ouriel K, Green RM. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion. J Vasc Surg 2001; 34:854-9. [PMID: 11700486 DOI: 10.1067/mva.2001.118589] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE The purposes of this study were to evaluate the safety and efficacy of limited-dose tissue plasminogen activator (t-PA) in patients with acute vascular occlusion and to compare these results with those obtained in equivalent patients receiving urokinase. METHODS We compared the results of 60 patients receiving catheter-directed urokinase from November 1997 to November 1998 (240,000 units/h x 4 h, 120,000 units/h thereafter for a maximum of 48 h) with those of 45 patients receiving catheter-directed t-PA from November 1998 to August 2000 (2 mg/h, total dose < or =100 mg) for acute arterial occlusion (AAO) and acute venous occlusion (AVO). Interventional approaches such as cross-catheter and coaxial techniques were used to reduce the dose of lytic agent needed to achieve pre-lysis-treatment goals (eg, complete lysis of all thrombus/unmasking graft stenosis or establishing outflow target). Statistical analysis was performed using Student t test and Fisher exact test. RESULTS The urokinase and t-PA groups were comparable with regard to age, comorbidities (coronary artery disease, hypertension, diabetes, renal insufficiency, smoking), duration of ischemic or occlusive symptoms, location of occlusive process, pretreatment with warfarin, and thrombotic versus embolic and native versus graft occlusion in patients with AAO. In patients with AAO and in those with AVO, t-PA was equivalent to or better than urokinase with regard to percent of clot lysis, incidence of major bleeding complications, limb salvage, and mortality. Achievement of pretreatment goals (arterial patients only) was 50% for urokinase patients and 76% for t-PA patients (P =.02). Analysis of success in individual pretreatment-goal achievement showed urokinase and t-PA to be equivalent in unmasking stenoses (85% and 84%, respectively; P = NS), whereas t-PA was superior to urokinase in the more critical task of establishing run-off (39% versus 81% for urokinase and t-PA, respectively; P =.001). Additional interventions, either endovascular or surgical, were required in 60% and 51% (P = NS) of patients receiving urokinase and t-PA, respectively, for AAO, and in 54% and 62% (P = NS) of patients receiving urokinase and t-PA, respectively, for AVO. CONCLUSIONS Limited-dose t-PA is a safe and effective therapy for AAO and AVO when administered by experienced teams using innovative but well-established interventional techniques.
Collapse
Affiliation(s)
- C K Shortell
- Division of Vascular Surgery, Department of Radiology, University of Rochester School of Medicine and Dentistry, NY 14621, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
Semba CP, Sugimoto K, Razavi MK. Alteplase and tenecteplase: applications in the peripheral circulation. Tech Vasc Interv Radiol 2001; 4:99-106. [PMID: 11981795 DOI: 10.1016/s1089-2516(01)90003-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Alteplase (t-PA), a recombinant analogue of human tissue plasminogen activator, became the first genetically engineered thrombolytic approved by the Food and Drug Administration in 1987 for acute myocardial infarction (AMI). In addition to AMI, alteplase is currently approved for the treatment of acute ischemic stroke and pulmonary embolism, and we anticipate approval for catheter clearance in late 2001 in a 2-mg vial configuration. With the withdrawal of human neonatal kidney cell-derived urokinase, alteplase has become an alternative agent in peripheral vascular applications. Because few interventionalists had prior experience with the handling and dosage of alteplase, the Advisory Panel to the Society of Cardiovascular and Interventional Radiology established practice guidelines for use in noncoronary applications. Emerging clinical experience with contemporary dosing regimens shows a safety and efficacy profile similar to urokinase but with significantly reduced drug costs. Tenecteplase (TNK) is a genetically modified version of alteplase. TNK is the only plasminogen activator available that has shown a significantly enhanced safety profile versus alteplase in AMI. Approved for a 5-second, single-bolus injection in AMI, TNK possesses a longer half-life, increased resistance to plasminogen activator inhibitor, and improved fibrin specificity compared with alteplase. Because of its enhanced safety profile, TNK may be a desirable agent for peripheral vascular applications. Initial clinical studies with TNK in acute arterial and venous disease are ongoing. This article outlines the Advisory Panel guidelines for using alteplase and highlights features of tenecteplase.
Collapse
Affiliation(s)
- C P Semba
- Cardiovascular Clinical Research, Genentech Inc., MS 59, 1 DNA Way, South San Francisco, CA 94080-4990, USA
| | | | | |
Collapse
|
10
|
Swischuk JL, Fox PF, Young K, Hussain S, Smouse B, Castañeda F, Brady TM. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications. J Vasc Interv Radiol 2001; 12:423-30. [PMID: 11287527 DOI: 10.1016/s1051-0443(07)61879-x] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
PURPOSE To determine the success and complication rates of intraarterial recombinant tissue-type plasminogen activator (rt-PA) infusion for the treatment of acute lower extremity artery and bypass graft occlusions. MATERIALS AND METHODS The results of 74 limbs in 70 patients (mean age, 66 y) treated with catheter-directed rt-PA infusion for the treatment of acute lower extremity ischemia were retrospectively evaluated. The group included 42 bypass grafts and 32 native arteries. All limbs were viable at presentation. The mean duration of symptoms was 11.9 days. rt-PA was infused for a mean of 27.9 hours for a mean total dose of 38.7 mg. Initial infusion rates of 3-6 mg/h were lowered to a preferred rate of 1.5 mg/h. Thrombolytic success was defined as 95% thrombolysis of an occluded segment with return of antegrade flow. Major bleeding complications were defined as any hemorrhagic event leading to surgery, extended or unexpected hospitalization, transfusion, death, intracranial hemorrhage, or a decrease in hemoglobin of 5 g/dL or in hematocrit of 15%. Thirty-day mortality and amputation rates were calculated. Patient characteristics and infusion parameters were evaluated as to whether they contributed to thrombolytic success or major bleeding events. RESULTS Thrombolytic success was achieved in 64 limbs (86%). Major bleeding complications occurred in 33 (47%) patients. In 22 of these patients, bleeding occurred at a vascular puncture site, whereas remote bleeding occurred in seven patients. Remote bleeding complications included two retroperitoneal hematomas, two rectus sheath hematomas, one lower gastrointestinal hemorrhage, one episode of hemoptysis, and one dehiscence of a femoral-popliteal bypass graft revision. No parameters were found to be predictive of thrombolytic success, whereas a negative history of smoking, increasing duration of infusion, and a low preprocedural ankle-brachial index (ABI) were found to be associated with major hemorrhagic events. Four patients (6%) underwent amputation and one patient (1%) died, resulting in a 30-day amputation-free survival rate of 93%. CONCLUSION Catheter-directed rt-PA infusion is effective in achieving thrombolysis. Despite a significant number of bleeding complications, 30-day mortality and amputation rates were favorable. Nonetheless, complication rates related to bleeding were not trivial and further evaluation with use of variable dosing regimens is indicated.
Collapse
Affiliation(s)
- J L Swischuk
- Department of Radiology, University of Illinois College of Medicine at Peoria, 1 Illini Dr., Peoria, IL 61605, USA.
| | | | | | | | | | | | | |
Collapse
|
11
|
Castañeda F, Smouse HB, Swischuk JL, Wyffels PL, Patel JC, Li R. Pharmacomechanical thrombolysis with use of the brush catheter in canine thrombosed femoropopliteal arterial PTFE bypass grafts. J Vasc Interv Radiol 2000; 11:503-8. [PMID: 10787211 DOI: 10.1016/s1051-0443(07)61385-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE To assess the efficacy, acute endothelial changes, and distal arterial emboli after use of the Cragg thrombolytic brush catheter in mature thrombosed polytetrafluoroethylene (PTFE) femoropopliteal arterial grafts in canines. MATERIALS AND METHODS PTFE femoropopliteal arterial grafts were implanted in 10 canines and were allowed to mature for approximately 4 weeks. The grafts were thrombosed by mechanical means and allowed to remain thrombosed for 24-72 hours. Through a left carotid cut-down, standard Seldinger arterial puncture was performed, followed by catheterization of the thrombosed graft. A soft, low-speed, brush (6 mm in diameter) aided by preprocedure pulse-spray urokinase infusion was utilized for thrombolysis. The native vessels, just proximal and distal to the anastomosis, were evaluated microscopically for endothelial damage. Arteriography was used for assessment of distal embolus. RESULTS All grafts were successfully thrombosed before thrombolysis. One graft could not be traversed with a wire and catheter and was, therefore, not treated. Immediate preprocedure pulse-spray urokinase infusion in the remaining nine grafts did not reconstitute antegrade flow in any instance and left significant amounts of residual thrombus in all treated grafts. Mechanical brush thrombolysis reconstituted antegrade flow in all nine treated grafts and complete graft thrombolysis was obtained in most. This was accomplished in a mean time of less than 4 minutes. Emboli were noted angiographically in 67% of cases. Histologic studies showed vessel wall damage limited to the intima or media in 67% of anastomoses. CONCLUSION This method offers a simple and rapid means of recanalizing thrombosed PTFE femoropopliteal arterial grafts in the studied model. This technique provides a means of rapidly "debulking" most intragraft thrombi. This may result in a shorter course of thrombolytic infusion. Potential benefits may include shortening the total treatment time and decreasing morbidity and cost associated with percutaneous thrombolysis. The occurrence of distal emboli in a majority of cases is a concerning limitation of this technique.
Collapse
Affiliation(s)
- F Castañeda
- Department of Radiology, University of Illinois College of Medicine at Peoria, 61605, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. J Vasc Interv Radiol 2000; 11:411-20. [PMID: 10787198 DOI: 10.1016/s1051-0443(07)61372-4] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K Valji
- Department of Radiology, UCSD Medical Center, San Diego, CA 92103, USA.
| |
Collapse
|
13
|
Davidian MM, Powell A, Benenati JF, Katzen BT, Becker GJ, Zemel G. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000; 11:289-94. [PMID: 10735421 DOI: 10.1016/s1051-0443(07)61419-5] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
PURPOSE To assess the feasibility and efficacy of reteplase in transcatheter arterial thrombolysis for lower extremity occlusive disease. MATERIALS AND METHODS Fifteen consecutive patients with acute lower extremity ischemia due to occlusive disease were treated by means of catheter-directed thrombolysis with reteplase. Following diagnostic angiography, thrombolysis was started either from an antegrade puncture site in cases of femoropopliteal occlusions, or from the contralateral groin in cases of thrombosis of the iliac artery, common femoral artery, or infrainguinal bypass grafts. Reteplase was infused at a rate of either 0.5 U/h (six patients) or 1.0 U/h (nine patients). RESULTS Complete thrombolysis was achieved in all of the nine (100%) patients in the 1.0 U/h group and in four of six (66%) patients in the 0.5 U/h group for a combined success rate of 13 of 15 (87%). Clinical success was achieved in 11 of 15 patients overall (73%). Major bleeding complications occurred in none of the 9 patients in the 1.0 U/h group and in one (16%) of the six patients in the 0.5 U/h group for an overall rate of 6%. CONCLUSIONS Reteplase shows promise as an alternative to urokinase in the treatment of lower extremity ischemia due to arterial occlusive disease.
Collapse
Affiliation(s)
- M M Davidian
- Miami Cardiac and Vascular Institute, Baptist Hospital, FL 33176, USA
| | | | | | | | | | | |
Collapse
|
14
|
Semba CP, Bakal CW, Calis KA, Grubbs GE, Hunter DW, Matalon TA, Murphy TP, Stump DC, Thomas S, Warner DL. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol 2000; 11:279-87. [PMID: 10735420 DOI: 10.1016/s1051-0443(07)61418-3] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- C P Semba
- Department of Interventional Radiology, Stanford University Medical Center, CA 94305, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 2000; 11:149-61. [PMID: 10716384 DOI: 10.1016/s1051-0443(07)61459-6] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE The clinical literature describing the use of alteplase in the treatment of peripheral arterial occlusive (PAO) disease is reviewed. MATERIALS AND METHODS The literature database was acquired by a MEDLINE search using the Boolean keyword string: tissue plasminogen activator and/or rt-PA and peripheral not animal. A review was performed to identify the dose range of alteplase, technique of infusion, use of anticoagulation, clinical success rates, and risk of complications. RESULTS Forty-six clinical studies were identified. There are few prospective, randomized clinical trials and a lack of standardized protocols and endpoints. Use of catheter-directed infusions of recombinant tissue plasminogen activator (rt-PA) may be beneficial versus surgery in the initial management of acute limb ischemia (< 14 days) and in reducing the magnitude of subsequent surgical or percutaneous revascularization. For patients with chronic limb ischemia (> 14 days), irreversible acute limb ischemia, or advanced diabetic arteriopathy, catheter-directed infusion of rt-PA or other plasminogen activators may be unsuitable. The risk of adverse bleeding appears related to the overall dose and duration of infusion. These risks appear similar to those of urokinase. The role of heparin in increasing adverse bleeding during rt-PA therapy is unclear. CONCLUSIONS There is no generally accepted dose or technique for administering catheter-directed thrombolysis using alteplase; however, several studies have demonstrated its clinical safety and efficacy. Formal studies will be required to determine the optimal dose, technique of infusion, the role of anticoagulation, and complication rates when alteplase is used for PAO disease.
Collapse
Affiliation(s)
- C P Semba
- Interventional Radiology, H-3646, Stanford University Medical Center, CA 94305, USA.
| | | | | | | | | |
Collapse
|
16
|
Johnson TR, Tobias JD. Initial Experience with Tissue Plasminogen Activator in Two Pediatric Oncology Patients. J Intensive Care Med 2000. [DOI: 10.1046/j.1525-1489.2000.00053.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Schweizer J, Altmann E, Stösslein F, Florek HJ, Kaulen R. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 1996; 22:129-32. [PMID: 8793432 DOI: 10.1016/0720-048x(96)00742-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Recanalization of the vascular lumen by means of local fibrinolysis is of major importance in the treatment of peripheral arterial occlusive disease. While urokinase and streptokinase have been extensively used for local fibrinolysis, there have been few studies of infiltration thrombolysis with genetically engineered tissue plasminogen activator (rt-PA). The aim of the investigation reported here was to establish whether there is any difference between urokinase and rt-PA in the short- and long-term outcome of local fibrinolytic therapy. One-hundred twenty patients (70 men, 50 women) with acute or subacute femoral (n = 21), femoropopliteal (n = 33), popliteal (n = 13) or popliteocrural (n = 53) thrombotic occlusions were randomized to local lysis using urokinase or rt-PA, and 6 months later follow-up investigations took place. Recanalization of thrombotically occluded vessels, particularly in the lower leg, was found more frequently, and after treatment of shorter duration, with rt-PA. Large local haematomas occurred in 8% of cases in the urokinase group and 15% in the rt-PA group. No serious haemorrhages were encountered in either group. Six months after treatment, the rt-PA group showed lower rates of Fontaine stage III and IV disease and amputation than the urokinase group, with a higher number of patients in Fontaine stage IIb. This study shows that local lysis with rt-PA yields better results than urokinase, not only in the short term but also 6 months later.
Collapse
Affiliation(s)
- J Schweizer
- Department of Angiology, Municipal Hospital, Dresden-Friedrichstadt, Germany
| | | | | | | | | |
Collapse
|
18
|
Abstract
Fibrinolytic therapy has become an accepted treatment modality for recent peripheral arterial and bypass graft occlusions and, in some cases, for chronic arterial occlusions. Streptokinase, urokinase, and tissue plasminogen activator have all been used for intraarterial infusion with varying protocols and results. This review focuses on dosing variables and clinical results for the various thrombolytic agents in peripheral arterial and bypass graft occlusions. Also discussed are new thrombolytic agents and the effects of concomitant use of other drugs as part of the treatment regimen.
Collapse
Affiliation(s)
- M F Meyerovitz
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
19
|
Abstract
The development of new thrombolytic agents and increased experience in the use of these drugs has enhanced limb salvage, especially in patients who have undergone multiple lower extremity bypass procedures. This article reviews the indications for such therapy and critically assesses both complications and efficacy of treatment.
Collapse
Affiliation(s)
- P Riggs
- Department of Surgery, University of Rochester, New York, USA
| | | |
Collapse
|
20
|
Clouse ME, Stokes KR, Perry LJ, Wheeler HG. Percutaneous intraarterial thrombolysis: analysis of factors affecting outcome. J Vasc Interv Radiol 1994; 5:93-100. [PMID: 8136603 DOI: 10.1016/s1051-0443(94)71461-5] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
PURPOSE The authors report results of high-dose thrombolytic therapy in native arteries and vein grafts and discuss the various factors affecting outcome. PATIENTS AND METHODS In a retrospective study, the outcome of 82 high-dose urokinase infusions in 76 patients was examined. Comorbid risk factors as they relate to outcome were studied extensively with log-linear analysis. Positive thrombolytic outcome (PTO) is defined as complete thrombolysis of a previously occluded segment with restoration of antegrade flow augmented by angioplasty or operative intervention to clear symptoms for 30 days. RESULTS The procedure resulted in a PTO in 63 of 82 instances (77%). The treatment was with urokinase alone in 39 cases (47%) and urokinase followed by surgery in 34 (41%), by angioplasty in four (5%), and by angioplasty in the proximal artery and peripheral vein grafting in five (6%). All stenoses associated with grafts were treated surgically. None of the following affected thrombolytic outcome: age of occlusion, heparin dose, catheter type, length or location of graft, or artery versus graft occlusion. The 30-day mortality was 6.1%, with a procedure-related mortality rate of 2.4%. Overall amputation rate was 18% (74% for patients in whom lysis failed by 30 days). CONCLUSION The presence of at least one runoff vessel was the most important factor affecting outcome (PTO, 95%; P = .00001, chi 2). The most important comorbid risk factor for failed thrombolysis was coronary artery disease (P = .03, chi 2).
Collapse
Affiliation(s)
- M E Clouse
- Department of Radiology, Deaconess Hospital, Boston, MA 02215
| | | | | | | |
Collapse
|
21
|
Dillon PW, Fox PS, Berg CJ, Cardella JF, Krummel TM. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. J Pediatr Surg 1993; 28:1264-8; discussion 1268-9. [PMID: 8263684 DOI: 10.1016/s0022-3468(05)80310-0] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Thrombotic vascular occlusion may complicate the clinical course of many neonatal and pediatric pathologic processes. Systemic thrombolytic therapy with heparin, urokinase, or streptokinase may not be appropriate in the critically ill neonate because these agents generate a diffuse coagulopathic state. Direct surgical intervention for repair may be precluded by the small size of the vessels involved. Recombinant tissue plasminogen activator (rTPA) induces only a minimal proteolytic state while inducing thrombolysis within the local environment of the clot. We report our experience with regional rTPA infusion in four critically ill patients with venous and arterial thrombotic disorders. there were two brachial artery occlusive lesions--a neonate with iatrogenic occlusion due to a misplaced intravenous catheter and a 2-year-old child with inadvertent arterial ligation during an attempted venous cutdown. Two venous lesions consisted of a full-term neonate with renal vein/inferior vena caval thrombosis and a 32-week infant with partial superior vena caval thrombosis due to a Broviac catheter. Systemic thrombolytic therapy was contraindicated in these patients because of underlying illnesses. Pretherapy vascular evaluation included Doppler examination and angiography. The rTPA infusion was continued until there was evidence of clot lysis by ultrasound, angiogram, or venogram. Infusion rate of rTPA was adjusted according to fibrinogen levels. All three neonates responded successfully to rTPA therapy. Two neonates required only bolus administration and one responded to combined bolus and continuous infusion therapy after 58 hours. rTPA failed to reverse brachial artery occlusion in the 2-year-old child with purpura fulminans.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- P W Dillon
- Department of Surgery, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033
| | | | | | | | | |
Collapse
|
22
|
Sprayregen S, Bakal CW, Cynamon J. Compression of vein graft by hematoma during fibrinolytic therapy simulating intrinsic venous stricture--a case report. Angiology 1993; 44:81-4. [PMID: 8424589 DOI: 10.1177/000331979304400114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Narrowing of a vein graft at an area of perigraft extravasation was encountered during fibrinolytic therapy for graft thrombosis. With cessation of fibrinolytic therapy, extravasation ceased and the vein lumen widened. Extrinsic compression and/or spasm due to a hematoma should be included as causes of vein graft narrowing in patients undergoing fibrinolytic therapy.
Collapse
Affiliation(s)
- S Sprayregen
- Department of Radiology, Montefiore Medical Center, New York, New York
| | | | | |
Collapse
|
23
|
Russell D, Madden KP, Clark WM, Zivin JA. Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration. Stroke 1992; 23:388-93. [PMID: 1542901 DOI: 10.1161/01.str.23.3.388] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND AND PURPOSE The main aim of our study was to assess the cerebrovascular thrombolytic efficacy of different tissue plasminogen activator treatment protocols with Doppler ultrasound. METHODS We occluded one internal carotid artery in 48 New Zealand White rabbits with whole blood emboli. Five minutes later the rabbits were assigned to receive one of the following tissue plasminogen activator protocols: 1) intravenous square-wave infusion in a total dose of 10 mg/kg, 2) intravenous constant infusion in a total dose of 10 mg/kg, 3) intravenous square-wave infusion in a total dose of 3 mg/kg, or 4) regional intra-arterial square-wave infusion in a total dose of 3 mg/kg. Blood flow velocities in the internal carotid arteries were continuously monitored during the study with Doppler ultrasound. RESULTS In all 12 animals treated with a 10-mg/kg square-wave intravenous tissue plasminogen infusion, internal carotid artery blood flow was reestablished within 2 hours (57.9 +/- 33.3 minutes) after the initiation of treatment, whereas this was the case for only six (50%) of the 12 animals treated with a constant 10-mg/kg intravenous tissue plasminogen activator infusion (p less than 0.05, Fisher's exact test). Internal carotid artery blood flow was restored within 2 hours (33.5 +/- 40.4 minutes) in all animals treated with a regional intra-arterial tissue plasminogen infusion in a total dose of 3 mg/kg and in only three (50%) of the six animals treated with the same dosage intravenously (p less than 0.05, signed rank test). CONCLUSIONS The thrombolytic efficacy of tissue plasminogen activator in the rabbit cerebral vasculature was superior when the same intravenous dose was given as a square-wave rather than a constant infusion and when the drug was given as a regional intra-arterial infusion rather than intravenously.
Collapse
Affiliation(s)
- D Russell
- University of California, School of Medicine, Department of Neurosciences, La Jolla 92093-0624
| | | | | | | |
Collapse
|
24
|
Berridge DC, Perkins AC, Frier M, Lonsdale RJ, Ballantyne KC, Wastie ML, Makin GS, Hopkinson BR. Detection and characterization of arterial thromboses using a platelet-specific monoclonal antibody (P256 Fab'). Br J Surg 1991; 78:1130-3. [PMID: 1933205 DOI: 10.1002/bjs.1800780931] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Arteriography does not reliably distinguish between acute and chronic arterial occlusions. Seventeen patients with acute lower limb ischaemia were investigated by arteriography and by imaging with a platelet-specific monoclonal antibody (P256 Fab'); 20 MBq 111In-labelled P256 Fab' was administered intravenously and patients were imaged at intervals of between 20 min and 24 h. Thirteen patients were subsequently treated with intra-arterial thrombolysis. In six the images showed foci of increased uptake of 111In-labelled P256 Fab' and the corresponding arterial segment was recanalized. Patency to 30 days was maintained in four cases. Seven patients had negative scans, only four of whom achieved lysis, and two of these suffered early rethrombosis. The remaining four patients were excluded from thrombolysis by the arteriographic appearances. 111In-labelled P256 Fab' imaging can identify sites of acute arterial thrombosis and may have clinical applications in the management of peripheral vascular disease. Further studies are required to test whether the technique has a role to play in patient selection for thrombolysis.
Collapse
Affiliation(s)
- D C Berridge
- Department of Vascular Surgery, University Hospital, Queen's Medical Centre, Nottingham, UK
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Dawson KJ, Reddy K, Platts AD, Hamilton G. Results of a recently instituted programme of thrombolytic therapy in acute lower limb ischaemia. Br J Surg 1991; 78:409-11. [PMID: 1903317 DOI: 10.1002/bjs.1800780409] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Twenty-eight patients with acute lower limb ischaemia received low dose intra-arterial thrombolytic therapy over a 2-year period. Eighteen patients received streptokinase and ten patients received recombinant tissue plasminogen activator (rTPA). Indications included arterial thromboemboli and graft failures. Mean ischaemic times were similar in both groups. Treatment time to achieve lysis was significantly less with rTPA (P less than 0.01). Subsequent vascular procedures, including angioplasty or reconstruction, were undertaken in 36 per cent of patients. Arterial puncture site bleeding occurred in eight (29 per cent) patients. Three (11 per cent) patients suffered rethrombosis after initial successful lysis. All rethromboses were successfully lysed with rTPA. There were two major amputations. Five (18 per cent) patients died, all lytic failures in the streptokinase treatment group. There were no cerebral haemorrhagic events and no patient died as a result of thrombolytic therapy. Good clinical outcome was obtained in nine of 18 patients treated with streptokinase and in nine of ten patients treated with rTPA. Intra-arterial thrombolysis provides effective therapy with high rates of limb salvage and a low mortality rate. This study suggests that rTPA may be a more effective agent, causing less morbidity, than streptokinase.
Collapse
Affiliation(s)
- K J Dawson
- Departments of Surgery, Royal Free Hospital, Hampstead, London, UK
| | | | | | | |
Collapse
|
26
|
Anderson BJ, Keeley SR, Johnson ND. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator. Anaesth Intensive Care 1991; 19:22-7. [PMID: 1901463 DOI: 10.1177/0310057x9101900104] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Four neonates suffered caval thrombosis secondary to indwelling central catheters. Dissolution of thrombus with recombinant tissue plasminogen activator (rt-PA) as a low-dose infusion (0.05 mg/kg/hr) directly into thrombus was successful in three patients. rt-PA was ceased after three days in the fourth patient because of catheter malposition. Thrombolysis was achieved between four and ten days. Rethrombosis occurred in one patient despite heparin prophylaxis. Plasminogen activator infusions were titrated to maintain fibrinogen levels above 100 mg/dl. One neonate suffered an intracranial haemorrhage. Regional rt-PA is an alternative to thrombectomy in critically ill neonates.
Collapse
Affiliation(s)
- B J Anderson
- Department of Intensive Care, Royal Children's Hospital, Melbourne, Victoria, Australia
| | | | | |
Collapse
|
27
|
Dawson K, Stansby G, Platts A, Hamilton G. Thrombolysis--a challenge for radiologists and surgeons. Clin Radiol 1990; 42:447-8. [PMID: 2261729 DOI: 10.1016/s0009-9260(05)80908-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
28
|
Anderson BJ, Keeley SR, Johnson ND. Prothrombinex-induced thrombosis and its management with regional plasminogen activator in hepatic failure. Med J Aust 1990; 153:352, 355-6. [PMID: 2122192 DOI: 10.5694/j.1326-5377.1990.tb136946.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Fulminant hepatic failure causes a bleeding diathesis as a result of impaired synthesis of hepatic clotting factors, thrombocytopenia, fibrinolysis and disseminated intravascular coagulation. Administration of clotting factor concentrates can cause thrombosis in patients with acute hepatic failure. Regional infusion of recombinant tissue-type plasminogen activator may be used to induce local thrombolysis. A case report of a five-year-old child is presented and the literature is reviewed.
Collapse
|
29
|
Dawson K, Stansby G, Novell R, Hehir D. Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: a preliminary report. J Vasc Surg 1990; 12:374-5. [PMID: 2118966 DOI: 10.1016/0741-5214(90)90165-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
30
|
Krupski WC. Reply. J Vasc Surg 1990. [DOI: 10.1016/0741-5214(90)90166-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
Dawson K, Stansby G, Hamilton G. Non-coronary thrombolysis. Lancet 1990; 336:250-1. [PMID: 1973800 DOI: 10.1016/0140-6736(90)91779-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
32
|
Rogers LQ, Lutcher CL. Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. Am J Med 1990; 88:389-95. [PMID: 2183600 DOI: 10.1016/0002-9343(90)90494-x] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A comprehensive review of the English literature evaluating streptokinase (SK) in the treatment of deep venous thrombosis (DVT) of the lower extremity reveals complete lysis of thrombi in as many as 70% of patients studied. The degree of lysis is affected by duration of symptoms before treatment, degree of occlusion, thrombus location, and development of a plasma proteolytic state. SK-treated patients have not been found to have a greater incidence of major hemorrhagic complications when compared with heparin-treated patients. SK is clearly beneficial in the treatment of DVT if patients are properly selected and carefully managed. Proper patient selection and a recommended treatment protocol are described.
Collapse
Affiliation(s)
- L Q Rogers
- Department of Medicine, Medical College of Georgia, Augusta 30912-3104
| | | |
Collapse
|
33
|
Krupski WC, Feldman RK, Rapp JH. Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: Preliminary report. J Vasc Surg 1989. [DOI: 10.1016/0741-5214(89)90130-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
34
|
Fourman S, Vaid K. Effects of Tissue Plasminogen Activator on Glaucoma Filter Blebs in Rabbits. Ophthalmic Surg Lasers Imaging Retina 1989. [DOI: 10.3928/1542-8877-19890901-20] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
35
|
Shewchun J, Sniderman KW. Fibrinolytic therapy in peripheral arterial grafts utilizing the "crossed two catheter" technique. Cardiovasc Intervent Radiol 1989; 12:110-2. [PMID: 2500242 DOI: 10.1007/bf02577402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Direct puncture of a thrombosed lower extremity bypass graft may be the only angiographic access to the graft when it cannot be opacified or cannulated by conventional angiographic techniques. In 1 patient, fibrinolytic therapy was performed from this approach using the "crossed two catheter" technique previously described for thrombosed dialysis grafts.
Collapse
Affiliation(s)
- J Shewchun
- Department of Radiology, Toronto General Hospital, Ontario, Canada
| | | |
Collapse
|
36
|
Bergstein JM. Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction. Kidney Int 1989; 35:14-8. [PMID: 2496256 DOI: 10.1038/ki.1989.2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
To study the effect of tissue plasminogen activator (TPA) therapy on glomerular fibrin deposition in the generalized Shwartzman reaction, rabbits were given an intravenous injection of TPA immediately following or three, four, or five hours after the second injection of endotoxin. Animals were sacrificed six hours after the second dose of endotoxin. Glomerular fibrin deposition was reduced in animals receiving TPA four hours after the second injection of endotoxin and was absent in animals receiving TPA five hours after the second dose of endotoxin. Glomerular fibrinolytic activity was reduced following development of the generalized Shwartzman reaction but was normal in animals that received TPA five hours after the second injection of endotoxin. TPA did not produce a systemic fibrinolytic state and did not prevent the decline in hematologic and coagulation factors typical of the Shwartzman reaction, despite the elimination of glomerular fibrin. These results suggest that TPA effectively removes glomerular thrombi in the generalized Shwartzman reaction and infers that TPA may be of value in the treatment of human diseases with similar pathology, such as the hemolytic uremic syndrome.
Collapse
Affiliation(s)
- J M Bergstein
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis
| |
Collapse
|
37
|
Gray M. Treating claudication. West J Med 1988. [DOI: 10.1136/bmj.296.6638.1738-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Fowler PBS. Treating claudication. West J Med 1988. [DOI: 10.1136/bmj.296.6638.1738-c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Oh VMS, Taylor EA. BRL 26830A and weight loss. West J Med 1988. [DOI: 10.1136/bmj.296.6638.1737-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
|
41
|
Berridge DC, Makin GS, Hopkinson BR. Treating claudication. BMJ : BRITISH MEDICAL JOURNAL 1988; 296:1738-9. [PMID: 3135902 PMCID: PMC2546120 DOI: 10.1136/bmj.296.6638.1738-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
42
|
Bircher MD. Deaths from injury. BMJ : BRITISH MEDICAL JOURNAL 1988; 296:1738. [PMID: 3135901 PMCID: PMC2546117 DOI: 10.1136/bmj.296.6638.1738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
43
|
Pernes J, Augusto MA, Vitoux J, Raynaud A, Fiessinger J, Brenot P, Fabiani J, Murday A, Gaux J. Local thrombolysis in peripheral arteries and bypass grafts. J Vasc Surg 1987. [DOI: 10.1016/0741-5214(87)90008-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Earnshaw JJ, Gregson RH, Makin GS, Hopkinson BR. Early results of low dose intra-arterial streptokinase therapy in acute and subacute lower limb arterial ischaemia. Br J Surg 1987; 74:504-7. [PMID: 3607411 DOI: 10.1002/bjs.1800740629] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Thirty-two patients with acute and subacute limb-threatening peripheral arterial ischaemia were treated with low dose intra-arterial streptokinase infusions. The mean duration of infusion was 38 h. Six patients developed pericatheter thrombosis and two had distal embolization of fragments of thrombus but in all cases these responded to repositioning the catheter and continuing the infusion. Five patients developed groin haematomata and in three of these there was evidence of a systemic fibrinolytic effect from the streptokinase with plasma fibrinogen reduced below 1 g/l. The most serious complication was perforation of the popliteal and tibial arteries which occurred on two occasions and required cessation of the infusion. Twenty-two patients (69 per cent) achieved limb salvage, eight (25 per cent) suffered a major amputation and two (6 per cent) died. The outcome was not related to the site, nature or duration of the arterial occlusion but patients with loss of sensation or paralysis of the affected limb were significantly less likely to obtain limb salvage (P = 0.001). For occlusions greater than 30 cm in length a new technique was used where the thrombus was lysed from distal to proximal in short lengths by gradual catheter withdrawal. This was successful in five out of six cases. Low dose intra-arterial streptokinase has been confirmed as an effective, relatively safe method of treatment in recent arterial ischaemia and can be recommended in situations where the results of surgery may not be favourable. In particular, patients with arterial thromboses and no distal run-off, distal and late arterial emboli, thrombosed popliteal aneurysms and patients after a failed embolectomy, have all been shown to respond to thrombolytic therapy with intra-arterial streptokinase.
Collapse
|
45
|
Earnshaw JJ, Westby JC, Makin GS, Hopkinson BR. Low dose intra-arterial streptokinase and acylated plasminogen-streptokinase activator complex: a retrospective review of two thrombolytic regimes in recent peripheral arterial ischaemia. EUROPEAN JOURNAL OF VASCULAR SURGERY 1987; 1:151-8. [PMID: 3332631 DOI: 10.1016/s0950-821x(87)80041-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Thrombolytic therapy was used for 57 patients with acute and sub-acute lower limb arterial ischaemia. In the first 34 patients a new thrombolytic agent, acylated plasminogen-streptokinase complex (BRL 26921) was assessed. Following this, 23 patients received low dose intra-arterial streptokinase. The two thrombolytic regimes have been analysed retrospectively. There were differences observed between the two groups in the type of patients treated and in the severity of limb ischaemia. Of the patients receiving BRL 26921, five (15%) had complete, and three (9%) partial lysis of the occluding thrombus. Serious bleeding occurred in six (18%) and minor bleeding in ten (29%) patients. After 30 days, twelve patients (35%) had limb salvage and eleven (32%) had died. Fifteen patients (65%) receiving intra-arterial streptokinase had lysis of the occluding thrombus. Minor bleeding was observed in three patients (13%). After 30 days, 15 (65%) had limb salvage and three (13%) had died. Patients receiving BRL 26921 had a significantly greater reduction in plasma fibrinogen and plasminogen concentrations during treatment which may have accounted for the bleeding complications. At the dose used, BRL 26921 had no demonstrable fibrinogen sparing effect. Improved lysis rates with fewer bleeding complications might be achieved by reducing the dose of BRL 26921. Low dose intra-arterial streptokinase has been confirmed as a safe, effective method of thrombolysis in recent peripheral arterial ischaemia.
Collapse
Affiliation(s)
- J J Earnshaw
- Vascular Surgery, University Hospital, Nottingham, U.K
| | | | | | | |
Collapse
|
46
|
Schubert W, Hunter DW, Guzman-Stein G, Ahrenholz DH, Solem LD, Dressel TD, Cunningham BL. Use of streptokinase for the salvage of a free flap: case report and review of the use of thrombolytic therapy. Microsurgery 1987; 8:117-21. [PMID: 3312924 DOI: 10.1002/micr.1920080303] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
This is the first case report of the clinical use of intraoperative streptokinase to promote free flap salvage. A latissimus dorsi free flap was mobilized to cover a scalping type injury. After 4 1/2 hours of ischemia and recurrent thrombosis, streptokinase was perfused into the thoracodorsal artery (7,500 units of streptokinase in 30 cc of normal saline). The free flap was exposed to this concentration of streptokinase for 10 minutes followed by drainage of the venous effluent in order to avoid possible deleterious systemic effects of the streptokinase. Good flow throughout the free flap resulted, and the flap remained viable, providing good coverage for the patient's skull. Controversies regarding the no-reflow phenomena and the use of various thrombolytic agents are discussed.
Collapse
Affiliation(s)
- W Schubert
- Department of Plastic and Reconstructive Surgery, University of Minnesota, Minneapolis
| | | | | | | | | | | | | |
Collapse
|